Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Colorcon
Merck
Baxter
Johnson and Johnson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204485

See Plans and Pricing

« Back to Dashboard

NDA 204485 describes VASOSTRICT, which is a drug marketed by Par Sterile Products and is included in one NDA. It is available from three suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VASOSTRICT profile page.

The generic ingredient in VASOSTRICT is vasopressin. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the vasopressin profile page.
Summary for 204485
Tradename:VASOSTRICT
Applicant:Par Sterile Products
Ingredient:vasopressin
Patents:6
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 204485
Generic Entry Date for 204485*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 204485
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485 NDA Par Pharmaceutical, Inc. 42023-164 42023-164-25 25 VIAL in 1 CARTON (42023-164-25) > 1 mL in 1 VIAL (42023-164-01)
VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485 NDA Par Pharmaceutical, Inc. 42023-190 42023-190-01 1 VIAL in 1 CARTON (42023-190-01) > 10 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength20UNITS/ML (20UNITS/ML)
Approval Date:Apr 17, 2014TE:RLD:Yes
Patent:  See PricingPatent Expiration:Jan 30, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Patent:  See PricingPatent Expiration:Jan 30, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Patent:  See PricingPatent Expiration:Jan 30, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKesson
Merck
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.